Stocksigma LogoStocksigma Logo

Suven Life Sciences Reallocates Rs 7,500 Lakh Preferential Issue Proceeds to Pipeline Development

Suven Life Sciences reported total utilization of Rs 53,763.36 lakh out of its Rs 85,764.02 lakh preferential issue proceeds up to 30th Sep'26, with Rs

Suven Life Sciences Reallocates Rs 7,500 Lakh Preferential Issue Proceeds to Pipeline Development

Suven Life Sciences Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 9:51 pm

Suven Life Sciences Reallocates Rs 7,500 Lakh Preferential Issue Proceeds to Pipeline Development Suven Life Sciences reported total utilization of Rs 53,763.36 lakh out of its Rs 85,764.02 lakh preferential issue proceeds up to 30th Sep'26, with Rs 12,813.06 lakh deployed during the quarter. Unutilized funds of Rs 32,000.66 lakh remain predominantly parked in fixed deposits and mutual funds. Shareholders approved a reallocation of Rs 7,500.00 lakh on 25th Aug'26, shifting capital from new R&D centre capex (reduced to Rs 12,500.00 lakh) to clinical development pipeline molecules at Suven Neurosciences (increased to Rs 47,500.00 lakh).

Original exchange filing (PDF)

More announcements from Suven Life Sciences Ltd

All Suven Life Sciences Ltd announcements